A clinical trial conducted in the midst of an Ebola epidemic in the Democratic Republic of Congo (DRC) has identified two new drugs that can dramatically cut mortality from the disease, and both are being immediately offered to all patients in an effort to control the country’s worst ever outbreak.
The Pamoja Tulinde Maisha (“together save lives” in Swahili) trial began last November, in four towns stricken by the outbreak. It compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3.
Preliminary data has convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.1
Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was not far behind. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.
Patients treated with ZMapp, the best known Ebola treatment candidate, which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate.
More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.
Researchers believe they can improve outcomes further in patients who are reached early in the course of infection. Among such patients, mortality rates were 6% with REGN-EB3, 11% with mAb114, 24% with ZMapp, and 33% with remdesivir.
Both REGN-EB3 and mAb114, like ZMapp, are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells.
Regeneron Pharmaceuticals made REGN-EB3, a cocktail of three such proteins, using antibodies from “humanised” mice infected with Ebola.
The US National Institute of Allergy and Infectious Diseases created mAb114 using antibodies isolated from the blood of a survivor of a 1995 outbreak in DRC. It will be developed by Ridgeback Therapeutics.
“From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe-Tamfum, director of the DRC’s Institut National de Recherche Biomédicale, which oversaw the trial. Full results are expected by early October and will appear in a peer reviewed journal soon thereafter.
Muyembe, who was part of the team that discovered the Ebola virus 43 years ago, and who in 1995 became the first doctor to harvest antibodies from survivors, told a press conference that the news of effective treatments would reinvigorate the campaign to end the current outbreak, which has struggled against deep local suspicion in a region plagued by insecurity.
“People think that if you enter a treatment centre, you’ll leave in a coffin,” said Muyembe. But with such high survival rates in the newly infected, he said, “We have a great message: a treatment centre is a place where you can recover and that you leave alive.”
The Latest on: Ebola
via Google News
The Latest on: Ebola
- ‘Not over the finish line’: Ebola vaccine development remains importanton October 28, 2019 at 11:31 am
The next generation of Ebola vaccines may be able to address deficiencies seen in the first generation, researchers said, highlighting the importance of continuing to evaluate new candidates even as ...
- When the president calls an Ebola crisis meeting on your daughter’s birthdayon October 28, 2019 at 7:30 am
Mathews Burwell was a mom of two before she became a member of President Barack Obama’s Cabinet. And to hear her tell it, sometimes that needed to take precedence, even amid an Ebola outbreak. It was ...
- Q&A: Should Ebola care be integrated into DRC's public health system?on October 28, 2019 at 5:50 am
Tristan Le Lonquer, an Ebola emergency coordinator with Médecins Sans Frontières, explains why they are setting up treatment zones within primary health care centers, and what the challenges are.
- Congo-Kinshasa: Dealing With Ebola in a Town Called Bingoon October 28, 2019 at 1:45 am
In the first of a four-part series of the impact of Ebola in the DRC, Laura Angela Bagnetto profiles the town of Bingo in North Kivu, eastern Democratic Republic of Congo. Workers carrying sacks of ...
- The U.S. has stopped Ebola before. But it may never repeat that success.on October 25, 2019 at 2:28 pm
In September 2014, the deadly Ebola virus was rampaging through West Africa. Dozens of people were being infected every day in three of the poorest nations in the world, and the health-care systems ...
- Scientists Were Hunting for the Next Ebola. Now the U.S. Has Cut Off Their Funding.on October 25, 2019 at 2:00 am
Arlette Kavugho, 40, mother of six and an Ebola survivor, carries Kambale Eloge, 16 months old, whose mother died of the disease, in Katwa, near Butembo, Democratic Republic of Congo. USAID’s Predict ...
- Researchers learn how Ebola virus disables the body's immune defenseson October 24, 2019 at 11:07 am
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can exert such catastrophic effects on the infected person. They've ...
- Brexit uncertainty, waning Ebola and an all-female spacewalkon October 23, 2019 at 6:13 am
The Ebola outbreak in the eastern Democratic Republic of the Congo (DRC) is finally waning, the World Health Organization (WHO) said on 18 October. Fifty people were diagnosed with Ebola in the DRC ...
- ‘The best in the world’: Putin lauds effectiveness of Russia’s revolutionary Ebola vaccineon October 23, 2019 at 3:38 am
SOCHI, October 23. /TASS/. President Vladimir Putin has said that he considered Russia’s groundbreaking Ebola-fighting vaccine to be the best in the world. Speaking at the plenary session of the ...
- Central African countries in talks on boosting anti-Ebola fighton October 22, 2019 at 6:45 am
Health ministers in 10 central African countries have held talks on boosting data sharing and cross-border surveillance in the fight against Ebola, the Democratic Republic of Congo announced Tuesday.
via Bing News